Download PDF
Dtsch Med Wochenschr 2015; 140(24): 1835-1838
DOI: 10.1055/s-0041-107770
Klinischer Fortschritt
Pneumologie
© Georg Thieme Verlag KG Stuttgart · New York

Immuntherapie beim Lungenkarzinom

Einsatz von Checkpoint-InhibitorenImmunotherapy in lung cancer: checkpoint inhibitors
Thomas Wehler   *
1   Thoraxonkologie, Klinik für Innere Medizin V, Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Universitätsklinikum des Saarlandes
,
Beatrice Wehler   *
2   III. Medizinsche Klinik und Poliklinik, Schwerpunkt Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz und Universitäres Centrum für Tumorerkrankungen (UCT) Mainz
,
Ingo Stehle
3   Onkologische Gemeinschaftspraxis, Schneiderstr. 12, 67655 Kaiserslautern
› Author Affiliations
Further Information

Publication History

Publication Date:
01 December 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Monoklonale Antikörper gegen den PD-1-Rezeptor oder seine Liganden sollen zur Wiederherstellung einer T-Zell-Antwort gegen Tumorantigene führen. Dieses immunologische Wirkprinzip ist mit dem Anti-PD-1-Antikörper Nivolumab kürzlich für die Therapie des Lungenkarzinoms zugelassen worden. Eine Gruppe von „Langzeitrespondern“ sowie ein insgesamt moderates Toxizitätsprofi machen diesen Therapieansatz besonders interessant.

Abstract

Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity.

Schlüsselwörter

Lungenkarzinom - Checkpoint-Inhibitoren - Immuntherapie - PD-1 - Nivolumab

Keywords

NSCLC - checkpoint inhibitors - immunotherapy - PD-1 - Nivolumab

* T. W. und B. W. teilen sich die Erstautorenschaft


 

  • Literatur

  • 1 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-1433
    CrossrefPubMedGoogle Scholar
  • 2 Spigel DR, Reckamp KL, Rizvi NA et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1) vs. docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer. J Clin Oncol 2015; 33 (suppl) abstract 8009
    PubMedGoogle Scholar
  • 3 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
    CrossrefPubMedGoogle Scholar
  • 4 Reckamp K, Spigel DR, Rizvi NA et al. Phase 3, global, randomized trial (CheckMate 017) of Nivolumab vs Docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC). 16th World Conference of Lung Cancer, 07. September 2015 Denver, USA: Abstract verfügbar auf http://library.iaslc.org/
    PubMedGoogle Scholar
  • 5 Hellmann MD, Creelan BC, Woo K et al. Smoking history and response to Nivolumab in patients with advanced NSCLCS. Ann Oncol 2014; 25 (Suppl. 04) iv429
    CrossrefPubMedGoogle Scholar
  • 6 Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128
    CrossrefPubMedGoogle Scholar
  • 7 Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (Check-Mate 057) of nivolumab versus docetaxel in advanced non-squamous cell non-small cell lung cancer. J Clin Oncol 2015; 33 (suppl, abstr LBA109)
    PubMedGoogle Scholar
  • 8 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
    CrossrefPubMedGoogle Scholar
  • 9 Garon EB, Rizvi NA et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028
    CrossrefPubMedGoogle Scholar
  • 10 Spira AL, Park K et al. Efficacy, safety, and predictive biomarker results from a randomized phase II study comparing MPDL3280A versus Docetaxel in 2L/3L (POPLAR). J Clin Oncol 2015; 33 (suppl; abstr 8010)
    PubMedGoogle Scholar
  • 11 Carbognin L, Pilotto S et al. Differential activity of Nivolumab, Pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015; 10 (06) e0130142
    CrossrefPubMedGoogle Scholar